{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'SUSPICION OF RHABDOMYOLYSIS', 'Muscular symptoms (myalgia, pain, weakness,', 'Systematic CPK assessment as per', 'dark urines)', 'protocol', 'y', 'Perform CPK', 'If Increase in CPK (expressed in ULN)', '> 3 ULN', 'Repeat immediately the count.', 'If confirmed, inform the local monitor and', 'INVESTIGATE for the origin:', '- PERFORM:', 'ECG', 'CPK-MB -MM', 'Troponin', 'Creatinine', 'Iono (k+, Ca\u00b2+)', 'Transaminases + Total and conjugated bilirubin', 'Myoglobin (serum and urines)', '- COLLECT/STORE one sample following handling procedures described in PK sections (for', 'studies with PK sampling) and freeze one serum sample (5 mL) on Day 1 (cessation of', 'investigational medicinal product).', '- INTERVIEW the patient about a recent intensive muscular effort, trauma, convulsions, electrical', 'injury, injury or stress to the skeletal muscle, multiple intramuscular injections, recent surgery,', 'concomitant medications, consumption of alcohol, morphine, cocaine.', '- SEARCH for alternative causes to cardiac or muscular toxicity, ie: stroke, pulmonary infarction,', 'dermatomyositis or polymyositis, convulsions, hypothyroidism, delirium tremens, muscular', 'dystrophies.', 'If the cardiac origin or the rhabdomyolysis is', 'If either the cardiac origin or the', 'ruled out and if CPK < 10 ULN:', 'rhabdomyolysis is confirmed or if CPK', 'MONITOR CPK every 3 days for the first week', '> 10 ULN:', 'then once weekly until return to normal or for', '1. DISCONTINUE Investigational', 'at least 3 months', 'Medicinal Product administration', '2. MONITOR CPK every 3 days for the', 'first week then once weekly until return', 'to normal or for at least 3 months', '3. HOSPITALIZATION should be', 'considered', 'Note for PK sampling: For pediatric PK sampling, only 2 mL of blood should be collected to', 'freeze 2 serum samples (0.5 mL each) on Day 1.', 'Suspicion of rhabdomyolysis is to be recorded as an AE only if at least 1 of the criteria in the', 'general guidelines for reporting adverse events in Section 10.4.3 is met.', 'Property of the Sanofi Group - strictly confidential', 'Page 169', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Appendix L', 'Definition of Anaphylaxis', '\"Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death.\\'', 'Adapted from:', 'Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF, Bock SA, Branum A, et al. Second symposium on the', 'definition and management of anaphylaxis: Summary report-Second National Institute of Allergy and Infectious', 'Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006;117:391-397', 'Clinical criteria for diagnosing anaphylaxis', 'Anaphylaxis is highly likely when any one of the following 3 criteria are fulfilled:', '1. Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal tissue, or both (eg, generalized hives, pruritus or', 'flushing, swollen lips-tongue-uvula)', 'AND AT LEAST ONE OF THE FOLLOWING', 'a. Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced PEF, hypoxemia)', 'b. Reduced BP or associated symptoms of end-organ dysfunction (eg, hypotonia [collapse], syncope, incontinence)', '2. Two or more of the following that occur rapidly after exposure to a likely allergen for that patient (minutes to several hours):', 'a. Involvement of the skin-mucosal tissue (eg, generalized hives, itch-flush, swollen lips-tongue-uvula)', 'b. Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced PEF, hypoxemia)', 'c.', 'Reduced BP or associated symptoms (eg, hypotonia [collapse], syncope, incontinence)', 'd.', 'Persistent gastrointestinal symptoms (eg, crampy abdominal pain, vomiting)', '3.', 'Reduced BP after exposure to known allergen for that patient (minutes to several hours):', 'a. Infants and children: low systolic BP (age specific) or greater than 30% decrease in systolic BP*', \"b. Adults: systolic BP of less than 90 mm Hg or greater than 30% decrease from that person's baseline\", 'PEF, Peak expiratory flow: BP, blood pressure.', '*Low systolic blood pressure for children is defined as less than 70 mm Hg from 1 month to 1 year, less than (70 mm Hg + [2: age]) from 1 to 10 years,', 'and less than 90 mm Hg from 11 to 17 years.', 'Property of the Sanofi Group - strictly confidential', 'Page 170', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}